
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY
I Background Information:
A 510(k) Number
K193053
B Applicant
Roche Diagnostics Operations Inc.
C Proprietary and Established Names
Tina-quant Hemoglobin A1cDx Gen.3
D Regulatory Information
Product Regulation
Classification Panel
Code(s) Section
21 CFR 862.1373 -
CH - Clinical
PDJ Class II Hemoglobin A1c Test
Chemistry
System
21 CFR 864.7470 -
LCP Class II Glycosylated HE - Hematology
hemoglobin assay
II Submission/Device Overview:
A Purpose for Submission:
New device.
B Measurand:
Glycosyclated Hemoglobin (HbA1c)
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
www.fda.gov

[Table 1 on page 1]
	Product		Classification		Regulation		Panel
	Code(s)				Section		
PDJ			Class II	21 CFR 862.1373 -
Hemoglobin A1c Test
System			CH - Clinical
Chemistry
LCP			Class II	21 CFR 864.7470 -
Glycosylated
hemoglobin assay			HE - Hematology

--- Page 2 ---
C Type of Test:
Quantitative turbidimetric inhibition immunoassay
III Intended Use/Indications for Use:
A Intended Use(s):
See Indications for Use below.
B Indication(s) for Use:
The Tina-quant Hemoglobin A1cDx Gen.3 assay is intended for use as an aid in diagnosis of
diabetes and as an aid in identifying patients who may be at risk for developing diabetes. It is an
in vitro diagnostics reagent system intended for quantitative determination of mmol/mol
hemoglobin A1c (IFCC) and % hemoglobin A1c (DCCT/NGSP) in hemolysate or venous whole
blood on the cobas c 503 clinical chemistry analyzer. HbA1c determinations are useful for
monitoring of long-term blood glucose control in individuals with diabetes mellitus.
C Special Conditions for Use Statement(s):
• Rx - For Prescription Use Only
• This device has significant negative interference with fetal hemoglobin (HbF). HbA1c results
are invalid for patients with abnormal amounts of HbF including those with known Hereditary
Persistence of Fetal Hemoglobin.
• For diagnostic purposes, mmol/mol HbA1c values (IFCC) and % HbA1c values
(DCCT/NGSP) should be used in conjunction with information from other diagnostic
procedures and clinical evaluations.
• The test is designed only for accurate and precise measurement of mmol/mol HbA1c (IFCC)
and % HbA1c (DCCT/NGSP). The individual results for total Hb and HbA1c concentration
should not be reported.
• Glycated HbF is not detected by the assay as it does not contain the β-chain that characterizes
HbA1c. However, HbF is measured in the total Hb assay and as a consequence, specimens
containing high amounts of HbF (>7%) may result in lower than expected mmol/mol HbA1c
values (IFCC) and % HbA1c values (DCCT/NGSP).
• As a matter of principle, care must be taken when interpreting any HbA1c result from patients
with Hb variants. Abnormal hemoglobins might affect the half life of the red cells or the in
vivo glycation rates. In these cases even analytically correct results do not reflect the same
level of glycemic control that would be expected in patients with normal hemoglobin.
Whenever it is suspected that the presence of an Hb variant (e.g. HbSS, HbCC or HbSC)
affects the correlation between the HbA1c value and glycemic control, HbA1c must not be
used for the diagnosis of diabetes mellitus.
• Hemoglobin A1c should not be used to diagnose diabetes mellitus in patients with a
hemoglobinopathy but normal red cell turnover (e.g. sickle cell trait).
• Any cause of shortened erythrocyte survival or decrease in mean erythrocyte age will reduce
exposure of erythrocytes to glucose with a consequent decrease in mmol/mol HbA1c values
(IFCC) and % HbA1c values (DCCT/NGSP), even though the time-averaged blood glucose
level may be elevated. Causes of shortened erythrocyte lifetime might be hemolytic anemia or
other hemolytic diseases, homozygous sickle cell trait, pregnancy, recent significant or
K193053 - Page 2 of 20

--- Page 3 ---
chronic blood loss, etc. Similarly, recent blood transfusions can alter the mmol/mol HbA1c
values (IFCC) and % HbA1c values (DCCT/NGSP). Caution should be used when
interpreting the HbA1c results from patients with these conditions. HbA1c must not be used
for the diagnosis of diabetes mellitus in the presence of such conditions.
• Hemoglobin A1c should not be used to diagnose diabetes mellitus in patients with hereditary
spherocytosis, malignancies or severe chronic hepatic and renal disease.3
• HbA1c should not be used to diagnose diabetes during pregnancy. It reflects the average
blood glucose levels over the preceding 3 months (the average life of a red blood cell), and
therefore may be falsely low during pregnancy or any other condition associated with recent
onset of hyperglycemia and/or decreased red cell survival.
• mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP) are not suitable for the
diagnosis of gestational diabetes.
• In cases of rapidly evolving type 1 diabetes the increase of HbA1c values might be delayed
compared to the acute increase in glucose concentrations. In these conditions diabetes mellitus
must be diagnosed based on plasma glucose concentration and/or the typical clinical
symptoms.
• Hemoglobin A1c testing should not replace glucose testing for type 1 diabetes, in pediatric
patients and in pregnant women.
D Special Instrument Requirements:
Roche cobas c 503 Clinical Chemistry Analyzer
IV Device/System Characteristics:
A Device Description:
The Tina-quant Hemoglobin A1cDx Gen.3 assay consists of two working reagents and a
Hemolyzing reagent. The R1 reagent consists of antibody reagent, MES buffer: 0.025 mol/L;
TRIS buffer: 0.015mol/L, pH6.2; HbA1c antibody (bovine serum): ≥0.5 mg/ml; stabilizers;
preservatives (liquid). R2 reagent (Polyhapten reagent) consists of MES buffer: 0.025 mol/L;
TRIS buffer: 0.015 mol/L, pH 6.2, HbA1c polyhapten: ≥ 8μg/mL; stabilizers; detergents and
preservatives (liquid). Anticoagulated whole blood is hemolyzed either manually or
automatically prior to determination of HbAlc .
The Tina-quant Hemoglobin A1cDx Gen.3 assay performs separate applications that are specific
to the sample types whole blood and hemolysate. The Whole Blood Application differs from the
Hemolysate Application in the hemolyzing step. For the Whole Blood Application, whole blood
samples are placed on the analyzer and hemolysis occurs onboard the analyzer. For the
Hemolysate Application, hemolyzed samples are placed on the analyzer and hemolysis occurs
manually before placing the samples onboard the analyzer. The two applications yield the same
results.
B Principle of Operation:
HbA1c determination is based on the turbidimetric inhibition immunoassay (TINIA) for
hemolyzed whole blood. Glycohemoglobin in the sample reacts with anti-HbA1c to form soluble
antigen-antibody complexes. Polyhaptens react with excess anti-HbA1c to form an insoluble
K193053 - Page 3 of 20

--- Page 4 ---
antibody-polyhapten complex which can be measured turbidimetrically. The instrument
calculates the %HbA1c from the HbA1c/Hb ratio according to a user selected protocol. This
method uses tetradecyltrimethylammonium bromide (TTAB) as the detergent in the hemolyzing
reagent to eliminate interference from leukocytes (TTAB does not lyse leukocytes). Sample
pretreatment to remove labile HbA1c is not necessary. All hemoglobin variants which are
glycated at the β -chain N-terminus and which have antibody-recognizable regions identical to
that of HbA1c are determined by this assay. Consequently, the metabolic state of patients having
uremia or the most frequent hemoglobinopathies (HbAS, HbAC, HbAE, HbAD) can be
determined using this assay.
V Substantial Equivalence Information:
A Predicate Device Name(s):
COBAS INTEGRA 800 Tina –quant HbA1cDx Gen.2 assay
B Predicate 510(k) Number(s):
k121291
C Comparison with Predicate(s):
Device & Predicate
K193053 K121291
Device(s):
Tina-quant COBAS INTEGRA 800
Device Trade Name Hemoglobin A1cDx Tina-quant HbA1cDx Gen.2
Gen.3 assay
General Device
Characteristic Similarities
This test is to be used as an
aid in diagnosis of diabetes
and as an aid in identifying
patients who may be at risk
Intended Use/Indications for developing diabetes.
Same
For Use HbA1c determinations are
useful for monitoring of
long-term blood glucose
control in individuals with
diabetes mellitus.
Polyclonal anti-HbA1c from
Antibody Same
sheep blood
General Device
Characteristic Differences
• Li-Heparin • Li-Heparin
Sample Types • K2-EDTA • K2-EDTA
• K3-EDTA • K3-EDTA
K193053 - Page 4 of 20

[Table 1 on page 4]
	Device & Predicate		K193053	K121291
	Device(s):			
Device Trade Name			Tina-quant
Hemoglobin A1cDx
Gen.3	COBAS INTEGRA 800
Tina-quant HbA1cDx Gen.2
assay
	General Device			
	Characteristic Similarities			
Intended Use/Indications
For Use			Same	This test is to be used as an
aid in diagnosis of diabetes
and as an aid in identifying
patients who may be at risk
for developing diabetes.
HbA1c determinations are
useful for monitoring of
long-term blood glucose
control in individuals with
diabetes mellitus.
Antibody			Same	Polyclonal anti-HbA1c from
sheep blood
	General Device			
	Characteristic Differences			
Sample Types			• Li-Heparin
• K2-EDTA
• K3-EDTA	• Li-Heparin
• K2-EDTA
• K3-EDTA

--- Page 5 ---
Device & Predicate
K193053 K121291
Device(s):
• Fluoride/potassium • Fluoride/potassium
oxalate
oxalate
• Na-Heparin
• Na-Heparin
• EDTA Fluoride • NaF/Na2-EDTA
VI Standards/Guidance Documents Referenced:
• CLSI EP05-A3, Evaluation of Precision Performance of Quantitative Measurement
Methods, 3rd edition
• CLSI EP06-A, Evaluation of the Linearity of Quantitative Measurement Procedures, 1st
edition
• CLSI EP17-A2, Evaluation of Detection Capability of Clinical Laboratory Measurement
Procedures, 2nd Edition
• The sponsor satisfied all special controls as outlined in 21 CFR 862.1373.
VII Performance Characteristics (if/when applicable):
A Analytical Performance:
1. Precision/Reproducibility:
Precision studies were conducted to evaluate repeatability (within-run precision) and
intermediate precision (within-laboratory precision) according the CLSI guideline EP05-A3.
Samples were prepared in K EDTA. Two aliquots per sample were measured once each, in
2
two runs per day, for 21 days, on 3 cobas c 503 analyzers and using 3 reagent lots per system.
Ten total samples were evaluated in each run: two controls, PreciControl HbA1c norm
(Control 1) and PreciControl HbA1c path (Control 2), and eight human samples with
approximate Hb1Ac concentrations of 4.9%, 6.6%, 7.3%, 8.2%, 12.5%, 14.6%, 12.3% and
13.1% for venous whole blood and 5.0%, 6.6%, 7.3%, 8.3%, 12.5%, 14.7%, 12.1% and
12.9% for hemolysate applications.
The samples were randomized within each run. For each sample, the following was
calculated: mean, repeatability and intermediate precision as CV and SD values and the
upper 95% confidence interval for SD and CV values. Results are summarized below:
Hemolysate Application, cobas c 503 Analyzer #1
Repeatability Intermediate
Mean Between-Run Between-Day Between-lot
(error) Precision (total)
% HbA1c
SD CV (%) SD CV (%) SD CV (%) SD CV (%) SD CV (%)
Hem 1 0.025 0.5 0.006 0.1 0.071 1.4 0.016 0.3 0.077 1.6
4.96
Hem 2 0.027 0.4 0.013 0.2 0.053 0.8 0.059 0.9 0.085 1.3
6.62
Hem 3 0.035 0.5 0.000 0.0 0.053 0.7 0.067 0.9 0.092 1.3
K193053 - Page 5 of 20

[Table 1 on page 5]
	Device & Predicate		K193053	K121291
	Device(s):			
			• Fluoride/potassium
oxalate
• Na-Heparin
• EDTA Fluoride	• Fluoride/potassium
oxalate
• Na-Heparin
• NaF/Na2-EDTA

[Table 2 on page 5]
Mean
% HbA1c	Repeatability
(error)		Between-Run		Between-Day		Between-lot		Intermediate
Precision (total)	
	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)
Hem 1
4.96	0.025	0.5	0.006	0.1	0.071	1.4	0.016	0.3	0.077	1.6
Hem 2
6.62	0.027	0.4	0.013	0.2	0.053	0.8	0.059	0.9	0.085	1.3
Hem 3	0.035	0.5	0.000	0.0	0.053	0.7	0.067	0.9	0.092	1.3

--- Page 6 ---
Repeatability Intermediate
Mean Between-Run Between-Day Between-lot
(error) Precision (total)
% HbA1c
SD CV (%) SD CV (%) SD CV (%) SD CV (%) SD CV (%)
7.32
Hem 4 0.039 0.5 0.009 0.1 0.056 0.7 0.083 1.0 0.108 1.3
8.32
Hem 5 0.057 0.5 0.011 0.1 0.100 0.8 0.203 1.6 0.234 1.9
12.54
Hem 6 0.077 0.5 0.013 0.1 0.148 1.0 0.268 1.8 0.316 2.1
14.77
Hem 7 0.055 0.5 0.023 0.2 0.100 0.8 0.181 1.5 0.215 1.8
12.14
Hem 8 0.072 0.6 0.000 0.0 0.111 0.9 0.188 1.5 0.230 1.8
12.94
Control 1 0.024 0.4 0.009 0.2 0.059 1.1 0.028 0.5 0.071 1.3
5.53
Control 2 0.055 0.5 0.026 0.2 0.085 0.8 0.146 1.3 0.179 1.6
10.89
Hemolysate Application, cobas c 503 Analyzer #2
Repeatability Intermediate
Mean Between-Run Between-Day Between-lot
(error) Precision (total)
% HbA1c
SD CV (%) SD CV (%) SD CV (%) SD CV (%) SD CV (%)
Hem 1 0.027 0.5 0.005 0.1 0.034 0.7 0.015 0.3 0.046 0.9
4.96
Hem 2 0.035 0.5 0.000 0.0 0.038 0.6 0.057 0.9 0.077 1.2
6.59
Hem 3 0.041 0.6 0.000 0.0 0.043 0.6 0.068 0.9 0.090 1.2
7.29
Hem 4 0.039 0.5 0.015 0.2 0.046 0.6 0.093 1.1 0.112 1.4
8.28
Hem 5 0.069 0.6 0.027 0.2 0.038 0.3 0.175 1.4 0.193 1.6
12.43
Hem 6 0.085 0.6 0.011 0.1 0.060 0.4 0.220 1.5 0.243 1.7
14.68
Hem 7 0.063 0.5 0.018 0.1 0.036 0.3 0.163 1.4 0.179 1.5
12.05
Hem 8 0.071 0.6 0.034 0.3 0.053 0.4 0.177 1.4 0.201 1.6
12.85
Control 1 0.030 0.5 0.008 0.1 0.029 0.5 0.024 0.4 0.049 0.9
5.52
Control 2 0.074 0.7 0.000 0.0 0.041 0.4 0.134 1.2 0.159 1.5
10.81
K193053 - Page 6 of 20

[Table 1 on page 6]
Mean
% HbA1c	Repeatability
(error)		Between-Run		Between-Day		Between-lot		Intermediate
Precision (total)	
	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)
7.32										
Hem 4
8.32	0.039	0.5	0.009	0.1	0.056	0.7	0.083	1.0	0.108	1.3
Hem 5
12.54	0.057	0.5	0.011	0.1	0.100	0.8	0.203	1.6	0.234	1.9
Hem 6
14.77	0.077	0.5	0.013	0.1	0.148	1.0	0.268	1.8	0.316	2.1
Hem 7
12.14	0.055	0.5	0.023	0.2	0.100	0.8	0.181	1.5	0.215	1.8
Hem 8
12.94	0.072	0.6	0.000	0.0	0.111	0.9	0.188	1.5	0.230	1.8
Control 1
5.53	0.024	0.4	0.009	0.2	0.059	1.1	0.028	0.5	0.071	1.3
Control 2
10.89	0.055	0.5	0.026	0.2	0.085	0.8	0.146	1.3	0.179	1.6

[Table 2 on page 6]
Mean
% HbA1c	Repeatability
(error)		Between-Run		Between-Day		Between-lot		Intermediate
Precision (total)	
	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)
Hem 1
4.96	0.027	0.5	0.005	0.1	0.034	0.7	0.015	0.3	0.046	0.9
Hem 2
6.59	0.035	0.5	0.000	0.0	0.038	0.6	0.057	0.9	0.077	1.2
Hem 3
7.29	0.041	0.6	0.000	0.0	0.043	0.6	0.068	0.9	0.090	1.2
Hem 4
8.28	0.039	0.5	0.015	0.2	0.046	0.6	0.093	1.1	0.112	1.4
Hem 5
12.43	0.069	0.6	0.027	0.2	0.038	0.3	0.175	1.4	0.193	1.6
Hem 6
14.68	0.085	0.6	0.011	0.1	0.060	0.4	0.220	1.5	0.243	1.7
Hem 7
12.05	0.063	0.5	0.018	0.1	0.036	0.3	0.163	1.4	0.179	1.5
Hem 8
12.85	0.071	0.6	0.034	0.3	0.053	0.4	0.177	1.4	0.201	1.6
Control 1
5.52	0.030	0.5	0.008	0.1	0.029	0.5	0.024	0.4	0.049	0.9
Control 2
10.81	0.074	0.7	0.000	0.0	0.041	0.4	0.134	1.2	0.159	1.5

--- Page 7 ---
Hemolysate Application, cobas c 503 Analyzer #3
Repeatability Intermediate
Mean Between-Run Between-Day Between-lot
(error) Precision (total)
% HbA1c
SD CV (%) SD CV (%) SD CV (%) SD CV (%) SD CV (%)
Hem 1 0.027 0.5 0.010 0.2 0.031 0.6 0.023 0.5 0.048 1.0
4.94
Hem 2 0.030 0.5 0.004 0.1 0.035 0.5 0.049 0.7 0.067 1.0
6.57
Hem 3 0.032 0.4 0.000 0.0 0.038 0.5 0.054 0.7 0.073 1.0
7.28
Hem 4 0.040 0.5 0.000 0.0 0.041 0.5 0.070 0.8 0.091 1.1
8.28
Hem 5 0.063 0.5 0.024 0.2 0.045 0.4 0.162 1.3 0.181 1.5
12.43
Hem 6 0.075 0.5 0.000 0.0 0.050 0.3 0.240 1.6 0.256 1.7
14.68
Hem 7 0.064 0.5 0.000 0.0 0.039 0.3 0.146 1.2 0.164 1.4
12.07
Hem 8 0.072 0.6 0.000 0.0 0.052 0.4 0.150 1.2 0.174 1.4
12.84
Control 1 0.026 0.5 0.008 0.2 0.035 0.6 0.024 0.4 0.050 0.9
5.49
Control 2 0.071 0.7 0.000 0.0 0.048 0.4 0.116 1.1 0.144 1.3
10.78
Hemolysate Application, All 3 analyzers (combined)
Repeatability Between- Reproducibility
Between-Run Between-Day Between-Lot
Mean % (error) Device (total)
HbA1c SD CV SD CV SD CV SD CV SD CV SD CV
(%) (%) (%) (%) (%) (%)
Hem 1 0.026 0.5 0.007 0.1 0.049 1.0 0.019 0.4 0.009 0.2 0.059 1.2
4.96
Hem 2 0.031 0.5 0.006 0.1 0.042 0.6 0.055 0.8 0.023 0.3 0.080 1.2
6.59
Hem 3 0.036 0.5 0.000 0.0 0.045 0.6 0.063 0.9 0.019 0.3 0.088 1.2
7.30
Hem 4 0.039 0.5 0.005 0.1 0.049 0.6 0.082 1.0 0.019 0.2 0.105 1.3
8.29
Hem 5 0.063 0.5 0.022 0.2 0.070 0.6 0.179 1.4 0.061 0.5 0.212 1.7
12.47
Hem 6 0.079 0.5 0.010 0.1 0.098 0.7 0.242 1.6 0.053 0.4 0.278 1.9
14.71
Hem 7 0.061 0.5 0.016 0.1 0.067 0.6 0.163 1.3 0.048 0.4 0.193 1.6
12.08
Hem 8 0.072 0.6 0.017 0.1 0.078 0.6 0.172 1.3 0.055 0.4 0.210 1.6
12.88
K193053 - Page 7 of 20

[Table 1 on page 7]
Mean
% HbA1c	Repeatability
(error)		Between-Run		Between-Day		Between-lot		Intermediate
Precision (total)	
	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)
Hem 1
4.94	0.027	0.5	0.010	0.2	0.031	0.6	0.023	0.5	0.048	1.0
Hem 2
6.57	0.030	0.5	0.004	0.1	0.035	0.5	0.049	0.7	0.067	1.0
Hem 3
7.28	0.032	0.4	0.000	0.0	0.038	0.5	0.054	0.7	0.073	1.0
Hem 4
8.28	0.040	0.5	0.000	0.0	0.041	0.5	0.070	0.8	0.091	1.1
Hem 5
12.43	0.063	0.5	0.024	0.2	0.045	0.4	0.162	1.3	0.181	1.5
Hem 6
14.68	0.075	0.5	0.000	0.0	0.050	0.3	0.240	1.6	0.256	1.7
Hem 7
12.07	0.064	0.5	0.000	0.0	0.039	0.3	0.146	1.2	0.164	1.4
Hem 8
12.84	0.072	0.6	0.000	0.0	0.052	0.4	0.150	1.2	0.174	1.4
Control 1
5.49	0.026	0.5	0.008	0.2	0.035	0.6	0.024	0.4	0.050	0.9
Control 2
10.78	0.071	0.7	0.000	0.0	0.048	0.4	0.116	1.1	0.144	1.3

[Table 2 on page 7]
Mean %
HbA1c	Repeatability
(error)		Between-Run		Between-Day		Between-Lot		Between-
Device		Reproducibility
(total)	
	SD	CV
(%)	SD	CV
(%)	SD	CV
(%)	SD	CV
(%)	SD	CV
(%)	SD	CV
(%)
Hem 1
4.96	0.026	0.5	0.007	0.1	0.049	1.0	0.019	0.4	0.009	0.2	0.059	1.2
Hem 2
6.59	0.031	0.5	0.006	0.1	0.042	0.6	0.055	0.8	0.023	0.3	0.080	1.2
Hem 3
7.30	0.036	0.5	0.000	0.0	0.045	0.6	0.063	0.9	0.019	0.3	0.088	1.2
Hem 4
8.29	0.039	0.5	0.005	0.1	0.049	0.6	0.082	1.0	0.019	0.2	0.105	1.3
Hem 5
12.47	0.063	0.5	0.022	0.2	0.070	0.6	0.179	1.4	0.061	0.5	0.212	1.7
Hem 6
14.71	0.079	0.5	0.010	0.1	0.098	0.7	0.242	1.6	0.053	0.4	0.278	1.9
Hem 7
12.08	0.061	0.5	0.016	0.1	0.067	0.6	0.163	1.3	0.048	0.4	0.193	1.6
Hem 8
12.88	0.072	0.6	0.017	0.1	0.078	0.6	0.172	1.3	0.055	0.4	0.210	1.6

--- Page 8 ---
Repeatability Between- Reproducibility
Between-Run Between-Day Between-Lot
Mean % (error) Device (total)
HbA1c SD CV SD CV SD CV SD CV SD CV SD CV
(%) (%) (%) (%) (%) (%)
Control 1 0.027 0.5 0.008 0.2 0.043 0.8 0.027 0.5 0.022 0.4 0.062 1.1
5.51
Control 2 0.067 0.6 0.000 0.0 0.062 0.6 0.132 1.2 0.054 0.5 0.169 1.6
10.83
Whole Blood Application, cobas c 503 Analyzer 1
Repeatability Intermediate
Mean Between-Run Between-Day Between-Lot
(error) Precision (total)
% HbA1c
SD CV(%) SD CV(%) SD CV(%) SD CV(%) SD CV(%)
WB 1 0.038 0.8 0.000 0.0 0.043 0.9 0.045 0.9 0.073 1.5
4.87
WB 2 0.026 0.4 0.015 0.2 0.030 0.4 0.071 1.1 0.083 1.3
6.60
WB 3 0.032 0.4 0.018 0.2 0.032 0.4 0.084 1.1 0.097 1.3
7.37
WB 4 0.039 0.5 0.008 0.1 0.048 0.6 0.089 1.1 0.108 1.3
8.24
WB 5 0.056 0.4 0.025 0.2 0.061 0.5 0.154 1.2 0.177 1.4
12.59
WB 6 0.079 0.5 0.043 0.3 0.067 0.5 0.168 1.1 0.202 1.4
14.69
WB 7 0.062 0.5 0.032 0.3 0.057 0.5 0.152 1.2 0.176 1.4
12.34
WB 8 0.061 0.5 0.015 0.1 0.055 0.4 0.165 1.3 0.185 1.4
13.14
Control 1 0.029 0.5 0.002 0.0 0.039 0.7 0.044 0.8 0.066 1.2
5.51
Control 2 0.055 0.5 0.011 0.1 0.057 0.5 0.129 1.2 0.152 1.4
11.20
Whole Blood Application, cobas c 503 Analyzer 2
Repeatability Intermediate
Mean Between-Run Between-Day Between-Lot
(error) Precision (total)
% HbA1c
SD CV(%) SD CV(%) SD CV(%) SD CV(%) SD CV(%)
WB 1 0.032 0.7 0.013 0.3 0.026 0.5 0.031 0.6 0.053 1.1
4.88
WB 2 0.031 0.5 0.010 0.2 0.025 0.4 0.077 1.2 0.087 1.3
6.58
WB 3 0.040 0.5 0.000 0.0 0.029 0.4 0.091 1.2 0.103 1.4
7.35
WB 4 0.042 0.5 0.011 0.1 0.035 0.4 0.106 1.3 0.120 1.5
8.21
WB 5 0.070 0.6 0.029 0.2 0.047 0.4 0.164 1.3 0.186 1.5
12.53
K193053 - Page 8 of 20

[Table 1 on page 8]
Mean %
HbA1c	Repeatability
(error)		Between-Run		Between-Day		Between-Lot		Between-
Device		Reproducibility
(total)	
	SD	CV
(%)	SD	CV
(%)	SD	CV
(%)	SD	CV
(%)	SD	CV
(%)	SD	CV
(%)
Control 1
5.51	0.027	0.5	0.008	0.2	0.043	0.8	0.027	0.5	0.022	0.4	0.062	1.1
Control 2
10.83	0.067	0.6	0.000	0.0	0.062	0.6	0.132	1.2	0.054	0.5	0.169	1.6

[Table 2 on page 8]
Mean
% HbA1c	Repeatability
(error)		Between-Run		Between-Day		Between-Lot		Intermediate
Precision (total)	
	SD	CV(%)	SD	CV(%)	SD	CV(%)	SD	CV(%)	SD	CV(%)
WB 1
4.87	0.038	0.8	0.000	0.0	0.043	0.9	0.045	0.9	0.073	1.5
WB 2
6.60	0.026	0.4	0.015	0.2	0.030	0.4	0.071	1.1	0.083	1.3
WB 3
7.37	0.032	0.4	0.018	0.2	0.032	0.4	0.084	1.1	0.097	1.3
WB 4
8.24	0.039	0.5	0.008	0.1	0.048	0.6	0.089	1.1	0.108	1.3
WB 5
12.59	0.056	0.4	0.025	0.2	0.061	0.5	0.154	1.2	0.177	1.4
WB 6
14.69	0.079	0.5	0.043	0.3	0.067	0.5	0.168	1.1	0.202	1.4
WB 7
12.34	0.062	0.5	0.032	0.3	0.057	0.5	0.152	1.2	0.176	1.4
WB 8
13.14	0.061	0.5	0.015	0.1	0.055	0.4	0.165	1.3	0.185	1.4
Control 1
5.51	0.029	0.5	0.002	0.0	0.039	0.7	0.044	0.8	0.066	1.2
Control 2
11.20	0.055	0.5	0.011	0.1	0.057	0.5	0.129	1.2	0.152	1.4

[Table 3 on page 8]
Mean
% HbA1c	Repeatability
(error)		Between-Run		Between-Day		Between-Lot		Intermediate
Precision (total)	
	SD	CV(%)	SD	CV(%)	SD	CV(%)	SD	CV(%)	SD	CV(%)
WB 1
4.88	0.032	0.7	0.013	0.3	0.026	0.5	0.031	0.6	0.053	1.1
WB 2
6.58	0.031	0.5	0.010	0.2	0.025	0.4	0.077	1.2	0.087	1.3
WB 3
7.35	0.040	0.5	0.000	0.0	0.029	0.4	0.091	1.2	0.103	1.4
WB 4
8.21	0.042	0.5	0.011	0.1	0.035	0.4	0.106	1.3	0.120	1.5
WB 5
12.53	0.070	0.6	0.029	0.2	0.047	0.4	0.164	1.3	0.186	1.5

--- Page 9 ---
Repeatability Intermediate
Mean Between-Run Between-Day Between-Lot
(error) Precision (total)
% HbA1c
SD CV(%) SD CV(%) SD CV(%) SD CV(%) SD CV(%)
WB 6 0.095 0.6 0.035 0.2 0.091 0.6 0.198 1.4 0.240 1.6
14.62
WB 7 0.078 0.6 0.000 0.0 0.035 0.3 0.176 1.4 0.195 1.6
12.25
WB 8 0.073 0.6 0.009 0.1 0.052 0.4 0.163 1.2 0.186 1.4
13.06
Control 1 0.036 0.6 0.000 0.0 0.028 0.5 0.044 0.8 0.063 1.1
5.51
Control 2 0.062 0.6 0.033 0.3 0.043 0.4 0.162 1.5 0.182 1.6
11.13
Whole Blood Application, cobas c 503 Analyzer 3
Intermediate
Repeatability
Mean Between-Run Between-Day Between-Lot Precision
(error)
% HbA1c (total)
SD CV(%) SD CV(%) SD CV(%) SD CV(%) SD CV(%)
WB 1 0.029 0.6 0 0.0 0.035 0.7 0.044 0.9 0.064 1.3
4.86
WB 2 0.031 0.5 0.009 0.1 0.025 0.4 0.080 1.2 0.090 1.4
6.55
WB 3 0.039 0.5 0.006 0.1 0.026 0.4 0.090 1.2 0.101 1.4
7.31
WB 4 0.043 0.5 0.012 0.2 0.036 0.4 0.096 1.2 0.111 1.4
8.17
WB 5 0.079 0.6 0.000 0.0 0.064 0.5 0.154 1.2 0.184 1.5
12.51
WB 6 0.082 0.6 0.000 0.0 0.107 0.7 0.191 1.3 0.234 1.6
14.62
WB 7 0.068 0.6 0.028 0.2 0.056 0.5 0.157 1.3 0.182 1.5
12.23
WB 8 0.083 0.6 0.000 0.0 0.064 0.5 0.162 1.2 0.193 1.5
13.05
Control 1 0.030 0.6 0.006 0.1 0.028 0.5 0.051 0.9 0.066 1.2
5.50
Control 2 0.071 0.6 0.000 0.0 0.043 0.4 0.137 1.2 0.160 1.4
11.10
Whole Blood Application, All 3 analyzers (combined)
Repeatability Between- Between- Reproducibility
Between-Day Between-Lot
Mean, (error) Run Device (total)
% HbA1c SD CV SD CV SD CV SD CV SD CV SD CV
(%) (%) (%) (%) (%) (%)
WB 1 0.034 0.7 0.004 0.1 0.036 0.7 0.040 0.8 0.007 0.1 0.064 1.3
4.87
K193053 - Page 9 of 20

[Table 1 on page 9]
Mean
% HbA1c	Repeatability
(error)		Between-Run		Between-Day		Between-Lot		Intermediate
Precision (total)	
	SD	CV(%)	SD	CV(%)	SD	CV(%)	SD	CV(%)	SD	CV(%)
WB 6
14.62	0.095	0.6	0.035	0.2	0.091	0.6	0.198	1.4	0.240	1.6
WB 7
12.25	0.078	0.6	0.000	0.0	0.035	0.3	0.176	1.4	0.195	1.6
WB 8
13.06	0.073	0.6	0.009	0.1	0.052	0.4	0.163	1.2	0.186	1.4
Control 1
5.51	0.036	0.6	0.000	0.0	0.028	0.5	0.044	0.8	0.063	1.1
Control 2
11.13	0.062	0.6	0.033	0.3	0.043	0.4	0.162	1.5	0.182	1.6

[Table 2 on page 9]
Mean
% HbA1c	Repeatability
(error)		Between-Run		Between-Day		Between-Lot		Intermediate
Precision
(total)	
	SD	CV(%)	SD	CV(%)	SD	CV(%)	SD	CV(%)	SD	CV(%)
WB 1
4.86	0.029	0.6	0	0.0	0.035	0.7	0.044	0.9	0.064	1.3
WB 2
6.55	0.031	0.5	0.009	0.1	0.025	0.4	0.080	1.2	0.090	1.4
WB 3
7.31	0.039	0.5	0.006	0.1	0.026	0.4	0.090	1.2	0.101	1.4
WB 4
8.17	0.043	0.5	0.012	0.2	0.036	0.4	0.096	1.2	0.111	1.4
WB 5
12.51	0.079	0.6	0.000	0.0	0.064	0.5	0.154	1.2	0.184	1.5
WB 6
14.62	0.082	0.6	0.000	0.0	0.107	0.7	0.191	1.3	0.234	1.6
WB 7
12.23	0.068	0.6	0.028	0.2	0.056	0.5	0.157	1.3	0.182	1.5
WB 8
13.05	0.083	0.6	0.000	0.0	0.064	0.5	0.162	1.2	0.193	1.5
Control 1
5.50	0.030	0.6	0.006	0.1	0.028	0.5	0.051	0.9	0.066	1.2
Control 2
11.10	0.071	0.6	0.000	0.0	0.043	0.4	0.137	1.2	0.160	1.4

[Table 3 on page 9]
Mean,
% HbA1c	Repeatability
(error)		Between-
Run		Between-Day		Between-Lot		Between-
Device		Reproducibility
(total)	
	SD	CV
(%)	SD	CV
(%)	SD	CV
(%)	SD	CV
(%)	SD	CV
(%)	SD	CV
(%)
WB 1
4.87	0.034	0.7	0.004	0.1	0.036	0.7	0.040	0.8	0.007	0.1	0.064	1.3

--- Page 10 ---
Repeatability Between- Between- Reproducibility
Between-Day Between-Lot
Mean, (error) Run Device (total)
% HbA1c SD CV SD CV SD CV SD CV SD CV SD CV
(%) (%) (%) (%) (%) (%)
WB 2 0.029 0.4 0.012 0.2 0.028 0.4 0.075 1.1 0.024 0.4 0.090 1.4
6.57
WB 3 0.037 0.5 0.009 0.1 0.032 0.4 0.087 1.2 0.027 0.4 0.104 1.4
7.34
WB 4 0.041 0.5 0.011 0.1 0.042 0.5 0.096 1.2 0.031 0.4 0.117 1.4
8.20
WB 5 0.069 0.5 0.020 0.2 0.062 0.5 0.155 1.2 0.043 0.3 0.187 1.5
12.54
WB 6 0.086 0.6 0.028 0.2 0.096 0.7 0.181 1.2 0.043 0.3 0.228 1.6
14.64
WB 7 0.070 0.6 0.023 0.2 0.055 0.5 0.159 1.3 0.055 0.4 0.192 1.6
12.27
WB 8 0.073 0.6 0.000 0.0 0.061 0.5 0.161 1.2 0.049 0.4 0.194 1.5
13.08
Control 1 0.032 0.6 0.002 0.0 0.032 0.6 0.047 0.8 0.007 0.1 0.065 1.2
5.51
Control 2 0.063 0.6 0.019 0.2 0.054 0.5 0.141 1.3 0.047 0.4 0.171 1.5
11.14
2. Linearity:
A linearity study was conducted using one dilution series, consisting of at 12 levels, prepared
using a spiked human whole blood pool with a % HbA1c concentration above the upper end
of the measuring range. A spiked human whole blood pool, containing purified human
HbA0, was used as the diluent; this human whole blood pool had a % HbA1c below the low
end of the measuring range. Samples were measured in triplicate, with the Whole Blood
Application, and data analysis was performed separately for each sample. Each sample was
prepared in K EDTA. Results of linear regression analysis were as follows:
2
Analyte Slope Intercept Pearson’s r
%HbA1c 0.95 0.563 0.9981
The linearity study is adequate to demonstrate that the Tina-quant Hemoglobin A1cDx Gen.3
assay is linear from 4.14 % HbA1c to 20.26 % HbA1c. This corresponds to a measuring
range of 23-196 mmol/mol HbA1c (IFCC) and 4.2-20.1 % HbA1c (DCCT/NGSP) at a
typical hemoglobin concentration of 13.2 g/dL (8.2 mmol/L).
Additionally, a linearity study was conducted according to CLSI EP06-A using two separate
dilution series, consisting of at least eleven levels, prepared for each glycated hemoglobin
(HbA1c) and total hemoglobin (Hb) using human hemolysate sample pools. The sample
pools include HbA1c and Hb concentrations above the upper end of the corresponding
measuring range. Each sample was prepared in K EDTA, and hemolyzing reagent was used
2
K193053 - Page 10 of 20

[Table 1 on page 10]
Mean,
% HbA1c	Repeatability
(error)		Between-
Run		Between-Day		Between-Lot		Between-
Device		Reproducibility
(total)	
	SD	CV
(%)	SD	CV
(%)	SD	CV
(%)	SD	CV
(%)	SD	CV
(%)	SD	CV
(%)
WB 2
6.57	0.029	0.4	0.012	0.2	0.028	0.4	0.075	1.1	0.024	0.4	0.090	1.4
WB 3
7.34	0.037	0.5	0.009	0.1	0.032	0.4	0.087	1.2	0.027	0.4	0.104	1.4
WB 4
8.20	0.041	0.5	0.011	0.1	0.042	0.5	0.096	1.2	0.031	0.4	0.117	1.4
WB 5
12.54	0.069	0.5	0.020	0.2	0.062	0.5	0.155	1.2	0.043	0.3	0.187	1.5
WB 6
14.64	0.086	0.6	0.028	0.2	0.096	0.7	0.181	1.2	0.043	0.3	0.228	1.6
WB 7
12.27	0.070	0.6	0.023	0.2	0.055	0.5	0.159	1.3	0.055	0.4	0.192	1.6
WB 8
13.08	0.073	0.6	0.000	0.0	0.061	0.5	0.161	1.2	0.049	0.4	0.194	1.5
Control 1
5.51	0.032	0.6	0.002	0.0	0.032	0.6	0.047	0.8	0.007	0.1	0.065	1.2
Control 2
11.14	0.063	0.6	0.019	0.2	0.054	0.5	0.141	1.3	0.047	0.4	0.171	1.5

[Table 2 on page 10]
Analyte	Slope	Intercept	Pearson’s r
%HbA1c	0.95	0.563	0.9981

--- Page 11 ---
for the diluent. Samples were measured in triplicate and data analysis was performed
separately for each sample.
Samples used to determine linearity spanned the following range:
Low end of linear range High end of linear range
Analyte
g/dL Mmol/L g/dL Mmol/L
Hb 3.04 1.89 40.4 25.1
HbA1c 0.293 0.182 2.87 1.78
Results of linear regression analysis were as follows:
Analyte Slope Intercept Pearson’s r
Hb 1.019 -0.1552 0.9999
HbA1c 0.991 -0.0026 0.9990
Results supported device linearity throughout the claimed measuring range of:
Hb: 4 – 40 g/dL (2.48 – 24.8 mmol/L)
HbA1c: 0.3 – 2.6 g/dL (0.186 – 1.61 mmol/L)
3. Analytical Specificity/Interference:
Endogenous Interferences
Studies were performed to evaluate several endogenous substances for potential interference
with measurement of % HbA1c using the candidate system. Pooled K EDTA whole blood
2
samples, with two hemoglobin A1c levels, one near the medical decision level
(approximately 6%) and one above it (approximately 9%), were spiked with the maximum
level of the above eight interferents, in separate preparations, resulting in sixteen spiked
samples. These samples were then hemolyzed with Tina-quant HbA1c Hemolyzing Reagent.
Another pool, without interferent, was equally hemolyzed. A greater than ten-level dilution
series was created for each of the sixteen spiked samples, using the interferent-free pools as
the diluent.
Each of the 10 dilutions of the sixteen samples were tested in replicates of 10, using one
reagent lot, one cobas c 503 analyzer, in a single run and within one calibration cycle. The
mean of the ten replicates was compared to the result from the reference sample (aliquot with
no interferent). For purposes of this experiment, the data was collected using the Hemolysate
Application and was representative of both Hemolysate and Whole Blood Applications. The
sponsor defined no significant interference as results that do not demonstrate more than 7%
deviation from the reference sample at either % HbA1c levels. The highest concentrations at
which no significant interference was observed are summarize below:
Highest Tested
Potential
Concentration without
Interferent
Significant Interference
Bilirubin 60 mg/dL
K193053 - Page 11 of 20

[Table 1 on page 11]
	Low end of linear range		High end of linear range	
Analyte				
	g/dL	Mmol/L	g/dL	Mmol/L
				
Hb	3.04	1.89	40.4	25.1
HbA1c	0.293	0.182	2.87	1.78

[Table 2 on page 11]
Analyte	Slope	Intercept	Pearson’s r
Hb	1.019	-0.1552	0.9999
HbA1c	0.991	-0.0026	0.9990

[Table 3 on page 11]
	Highest Tested
Potential	
	Concentration without
Interferent	
	Significant Interference
	
Bilirubin	60 mg/dL

--- Page 12 ---
Highest Tested
Potential
Concentration without
Interferent
Significant Interference
Ditaurobilirubin 60 mg/dL
Triglycerides 1594 mg/dL
Rheumatoid
750 IU/mL
Factors
Total Protein 21 g/dL
Albumin 60 g/L
Immunoglobulin
60 g/L
(IgG)
Glucose 1000 mg/dL
The labeling states that no significant interference (defined as <7% interference) was
observed for the above endogenous interferents at the concentrations listed.
Exogenous Interferences – Drugs
Drug interference testing was performed with hemolysate samples at two different HbA1c
levels, approximately 6% and 9% HbA1c. Each drug was added in two defined
concentrations with concentration one being several times (typically five times) the
maximum daily dosage and concentration 2 being the maximum daily dosage level. Samples
were prepared in K EDTA and measured in ten-fold using the cobas c 503 analyzer. The
2
median value was compared to the reference value (HbA1c sample with no drug added) and
the deviation from the reference was calculated. Interference was defined as median values
which were ≤7% deviation from the reference sample. Drug interference studies were
conducted using the Hemolysate Application and were representative of both Hemolysate
and Whole Blood Applications.
Highest Tested Concentration
Potential
without Significant Interference
Interferent
(mg/dL)
Acetaminophen 20
Acetylsalicylic
100
acid
Ampicillin-Na 100
Ascorbic acid 30
Cefoxitin (A) 250
Cefoxitin (B) 660
Cyclosporine 0.5
Doxycyclin 5.0
Gammagard 6000
Heparin 5000 IU/L
Ibuprofen 50
K193053 - Page 12 of 20

[Table 1 on page 12]
	Highest Tested
Potential	
	Concentration without
Interferent	
	Significant Interference
	
Ditaurobilirubin	60 mg/dL
Triglycerides	1594 mg/dL
Rheumatoid
Factors	750 IU/mL
Total Protein	21 g/dL
Albumin	60 g/L
Immunoglobulin
(IgG)	60 g/L
Glucose	1000 mg/dL

[Table 2 on page 12]
	Highest Tested Concentration
Potential	
	without Significant Interference
Interferent	
	(mg/dL)
	
Acetaminophen	20
Acetylsalicylic
acid	100
Ampicillin-Na	100
Ascorbic acid	30
Cefoxitin (A)	250
Cefoxitin (B)	660
Cyclosporine	0.5
Doxycyclin	5.0
Gammagard	6000
Heparin	5000 IU/L
Ibuprofen	50

--- Page 13 ---
Highest Tested Concentration
Potential
without Significant Interference
Interferent
(mg/dL)
Levodopa 2.0
Methyldopa 2.25
Metronidazole 20
N-Acetylcysteine 166
Phenylbutazone 40
Rifampicin 6.0
Theophylline 10
Tolbutamide 300
No interference was observed at approximately 6% or approximately 9% HbA1c for the
drugs evaluated at the concentrations tested. No interference was observed at expected
therapeutic concentrations with these drugs. The labeling states that no significant
interference (defined as >7% shift in recovery value) was observed for drugs at the
concentrations listed in the table above.
Cross-Reactivity
Studies were conducted to evaluate the Tina-quant Hemoglobin A1cDx Gen.3 assay on the
cobas c 503 analzyer for potential cross-reactivity with hemoglobin fractions and glycated
albumin. Two HbA1c concentrations of pooled whole blood (~6% and ~ 9%) were each
mixed with pools of potential cross-reactants, and the % HbA1c values of the samples mixed
with interferent pools were compared to the control samples with no interferent. Samples
were prepared in K EDTA.
2
Ten replicates of each sample were analyzed using one reagent lot on one cobas c503
analyzer in a single run. For purposes of this experiment, the data was collected using the
Hemolysate Application and was representative of both Hemolysate and Whole Blood
Applications. The sponsor defined no significant interference as a difference of no more than
7% from the control sample at both % HbA1c levels. The highest concentrations at which no
significant interference was observed are summarize below:
Highest Tested
Cross reactant Concentration without
Significant Interference
HbA0 120 g/dL
HbA1(a+b) 0.96 g/dL
Carbamylated Hb 2.0 g/dL
Acetylated Hb 2.0 g/dL
Glycated Albumin 10 g/dL
Labile HbA1c 1000 mg/dL
K193053 - Page 13 of 20

[Table 1 on page 13]
	Highest Tested Concentration
Potential	
	without Significant Interference
Interferent	
	(mg/dL)
	
Levodopa	2.0
Methyldopa	2.25
Metronidazole	20
N-Acetylcysteine	166
Phenylbutazone	40
Rifampicin	6.0
Theophylline	10
Tolbutamide	300

[Table 2 on page 13]
	Highest Tested
Cross reactant	Concentration without
	Significant Interference
HbA0	120 g/dL
HbA1(a+b)	0.96 g/dL
Carbamylated Hb	2.0 g/dL
Acetylated Hb	2.0 g/dL
Glycated Albumin	10 g/dL
Labile HbA1c	1000 mg/dL

--- Page 14 ---
The sponsor’s labeling states the following: No cross reactions with HbA0, HbA1a, HbA1b,
acetylated hemoglobin, carbamylated hemoglobin, glycated albumin and labile HbA1c were
found for the anti-HbA1c antibodies used in this kit.
Hemoglobin Variants
Hemoglobin variant testing was conducted to determine if significant interference with any
of the major hemoglobin variants occurred when using the Tina-quant Hemoglobin A1cDx
Gen.3 assay on cobas c 503 analyzer. The most common hemoglobin variants are HbS, HbC,
HbD and HbE. The following is a table of samples that were measured (samples were
prepared in K EDTA):
2
Hemoglobin
Number of Samples % Variant HbA1c %
Variant
HbS 30 35-41 % HbS 4.35 - 12.7
HbC 30 28-37 % HbC 4.90 - 14.1
HbE 30 24-27 % HbE 5.17 - 10.0
HbD 29 36-42 % HbD 5.17 - 9.70
HbA2 15 4.3-6.5 % HbA2 5.10 - 9.80
Elevated HbF 19 3.2-39 % HbF 6.10 -9.30
Each sample was tested once, in on a cobas c 503 analyzer. Results obtained with the Tina-
quant Hemoglobin A1cDx Gen.3 assay on the cobas c 503 analyzer were compared to those
obtained with the corresponding comparator method. For purposes of this experiment, the
data was collected using the Hemolysate Application and was representative of both
Hemolysate and Whole Blood Applications. Results were determined as described in the
table below:
Approximately 6% HbA1c Approximately 9% HbA1c
Hemoglobin
Relative % Relative %
Variant Range Range
difference Difference
HbS -2.5 % -7.2 – 3.2 -4.0 % -9.3 – (-2.0)
HbC -3.9 % -7.7– 2.8 -6.0 % -4.6 – (-3.6)
HbE 0.1 % -5.5 – 5.7 -1.2 % -5.2 – 0.6
HbD -1.8 % -4.5 – 3.0 -2.6 % -3.3 – 0.2
HbA2 -1.0 % -4.1– 2.7 0.4 % -2.2 – 1.1
HbF Specimens containing high amounts of HbF (>7 %) may yield lower than
expected HbA1c values.
The sponsor has included the following prominent boxed warning in the labeling: “This
device has significant negative interference with fetal hemoglobin (HbF). HbA1c results are
invalid for patients with abnormal amounts of HbF including those with known Hereditary
Persistence of Fetal Hemoglobin. Refer to the Limitations - interference section of this
method sheet for details.
K193053 - Page 14 of 20

[Table 1 on page 14]
Hemoglobin			
	Number of Samples	% Variant	HbA1c %
Variant			
			
HbS	30	35-41 % HbS	4.35 - 12.7
HbC	30	28-37 % HbC	4.90 - 14.1
HbE	30	24-27 % HbE	5.17 - 10.0
HbD	29	36-42 % HbD	5.17 - 9.70
HbA2	15	4.3-6.5 % HbA2	5.10 - 9.80
Elevated HbF	19	3.2-39 % HbF	6.10 -9.30

[Table 2 on page 14]
	Approximately 6% HbA1c		Approximately 9% HbA1c	
Hemoglobin				
	Relative %		Relative %	
Variant		Range		Range
	difference		Difference	
				
HbS	-2.5 %	-7.2 – 3.2	-4.0 %	-9.3 – (-2.0)
HbC	-3.9 %	-7.7– 2.8	-6.0 %	-4.6 – (-3.6)
HbE	0.1 %	-5.5 – 5.7	-1.2 %	-5.2 – 0.6
HbD	-1.8 %	-4.5 – 3.0	-2.6 %	-3.3 – 0.2
HbA2	-1.0 %	-4.1– 2.7	0.4 %	-2.2 – 1.1
HbF	Specimens containing high amounts of HbF (>7 %) may yield lower than
expected HbA1c values.			

--- Page 15 ---
4. Assay Reportable Range:
See Linearity as described in section A.2, above.
5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):
Traceability:
The assigned HbA1c and total hemoglobin values of the cobas c 513 Tina-quant Hemoglobin
A1c Gen.3 assay is certified with the National Glycohemoglobin Standardization Program
(NGSP). See NGSP website for current certification at http://www.ngsp.org.
The derived result of the ratio (%) from the NGSP correlation is calculated from the
individual quantitative results for total hemoglobin and Hemoglobin A1c (HbA1c). The
International Federation of Clinical Chemistry (IFCC) units of mmol/mol are calculated
using the Master Equation: IFCC = (NGSP- 2.15) / 91.5. Two different units are provided to
the customers: NGSP equivalent units (%) and IFCC equivalents units (mmol/mol).
6. Detection Limit:
Limits of blank and detection were determined according to EP17-A2. For determination of
Limit of Blank (LoB) one analyte free K EDTA. sample was measured with three lots in 10-
2
fold determination. Six runs distributed over ≥ 3 days using one cobas c 503 analyzer were
performed. In total, 60 measurements were obtained per lot. LoB was defined by the sponsor
as the 95th percentile of the 60 measured values. In their design (n=60) the 95th percentile
was the average of the 57th and 58th value.
For determination of the limit of detection (LoD), five unique human samples in K EDTA
2
with low-analyte concentrations were measured with three lots of Tina-quant Hemoglobin
A1cDx Gen.3 in two-fold determinations. The measurements were performed in six runs,
over ≥ three days, on one cobas c 503 analyzer. In total, 60 measurements were obtained per
lot. LoD is defined as the concentration, at which there is a 95% probability that a sample
contains analyte. Results for LoB and LoD determination are described in the tables below:
Hb LoB HbA1c LoB
0.0530 mmol/L 0.085 g/dL 0.0220 mmol/L 0.035 g/dL
Hb LoD HbA1c LoD
0.119 mmol/L 0.192 g/dL 0.0437 mmol/L 0.07 g/dL
These results correspond to a Limit of Blank of 15 mmol/mol (IFCC) and 3.5 % HbA1c
(DCCT/NGSP) and a Limit of Detection of 22 mmol/mol (IFCC) and 4.2 % HbA1c
(DCCT/NGSP) at a typical hemoglobin concentration of 13.2 g/dL (8.2 mmol/L).
7. Assay Cut-Off:
Not applicable.
K193053 - Page 15 of 20

[Table 1 on page 15]
Hb LoB		HbA1c LoB	
0.0530 mmol/L	0.085 g/dL	0.0220 mmol/L	0.035 g/dL

[Table 2 on page 15]
Hb LoD		HbA1c LoD	
0.119 mmol/L	0.192 g/dL	0.0437 mmol/L	0.07 g/dL

--- Page 16 ---
B Comparison Studies:
1. Method Comparison with Predicate Device:
A method comparison study was performed to compare the sample results from the candidate
method, Hemoglobin A1cDx Gen.3 assay on the cobas c 503 analzyer, to results from a
secondary NGSP reference laboratory using the Tosoh Automated Glycohemoglobin
Analyzer HLC-723G8 (Tosoh HPLC system), the NGSP method.
The study was conducted with both the Tina-quant Hemoglobin A1cDx Gen.3 Whole Blood
Application and Hemolysate Application.
One hundred and seventy-one whole blood samples and one hundred seventy-three
hemolysate samples from the secondary NGSP reference laboratory were used in the
evaluation. These samples were measured by the secondary NGSP reference laboratory using
the Tosoh HPLC system and the Roche Tina-quant Hemoglobin A1cDx Gen.3 test system.
The samples were all native and were tested over a 3 day period, with one lot of reagent, on
one cobas c 503 analyzer using K EDTA as the anti-coagulant. Deming (weighted), Passing-
2
Bablok regression and linear regression analyses were performed for the whole blood
application versus the comparator method and the hemolysate application versus the
comparator method. The distribution of samples used in the study is summarized below:
# Samples Tested % Samples Tested
% HbA1c
Whole Blood Hemolysate Whole Blood Hemolysate
≤ 5% 6 6 3.5% 3.5%
5-6 % 23 24 13.5% 13.9%
>6 – 6.5% 31 32 18.1% 18.5%
>6.5 – 7% 37 37 21.6% 21.4%
>7 – 8% 25 25 14.6% 14.5%
>8 – 9% 13 13 7.6% 7.5%
>9% 36 36 21.1% 20.8%
Total 171 173 100% 100%
The tables below summarize the bias between the Tina-quant Hemoglobin A1cDx Gen.3
assay and the NGSP Tosoh reference method.
Regression Analysis (whole blood):
Whole Blood y-intercept Slope
-0.190 1.019
Deming
95% CI: -0.296-(-0.085) 95% CI: 1.004-1.034
-0.271 1.030
Passing-Bablok
95% CI: -0.399-(-0.141) 95% CI: 1.011-1.050
-0.0734 1.003
Linear Regression
95% CI:-0.151-0.004 95% CI:0.994-1.012
K193053 - Page 16 of 20

[Table 1 on page 16]
	# Samples Tested		% Samples Tested	
% HbA1c				
	Whole Blood	Hemolysate	Whole Blood	Hemolysate
				
≤ 5%	6	6	3.5%	3.5%
5-6 %	23	24	13.5%	13.9%
>6 – 6.5%	31	32	18.1%	18.5%
>6.5 – 7%	37	37	21.6%	21.4%
>7 – 8%	25	25	14.6%	14.5%
>8 – 9%	13	13	7.6%	7.5%
>9%	36	36	21.1%	20.8%
Total	171	173	100%	100%

[Table 2 on page 16]
	Whole Blood			y-intercept			Slope	
Deming			-0.190
95% CI: -0.296-(-0.085)			1.019
95% CI: 1.004-1.034		
Passing-Bablok			-0.271
95% CI: -0.399-(-0.141)			1.030
95% CI: 1.011-1.050		
Linear Regression			-0.0734
95% CI:-0.151-0.004			1.003
95% CI:0.994-1.012		

--- Page 17 ---
Regression Analysis (hemolysate):
Hemolysate y-intercept Slope
-0.0589 0.999
Deming
95% CI: -0.046-0.164 95% CI: 0.984-1.015
-0.0479 1.016
Passing-Bablok
95% CI: -0.173-0.060 95% CI: 1.000-1.034
0.215 0.979
Linear Regression
95% CI:0.139-0.292 95% CI:0.970-0.988
The predicted bias at HbA1c concentrations near clinical decision points, as determined by
Passing/Bablok regression, are described below:
% Bias (Whole % Relative Bias % Bias % Relative Bias
% HbA1c
Blood) (Whole Blood) (Hemolysate) (Hemolysate)
5% -0.121 -2.4% 0.031 0.6%
6.5% -0.076 -1.2% 0.055 0.8%
8% -0.031 -0.4% 0.078 1.0%
12% 0.089 0.7% 0.142 1.2%
Total Error:
Total error (%TE) was calculated for both the Hemolysate and Whole Blood Applications
using the following equation:
%TE = |%Bias| + 1.96 * %CV * (1 + %Bias/100)
The %Bias component was generated during the method comparison studies using the
Passing-Bablok regression data and is the %Bias shown in the table below. The variance
component (%CV) was generated during the precision studies and represents the total
reproducibility shown in the table below:
Total Error Summary – Hemolysate
Hemolysate Precision Total Error
%HbA1c % Bias
sample (%CV) (%)
1 4.96 0.63 1.2 3.0
2 6.59 0.87 1.2 3.3
3 7.30 0.94 1.2 3.3
4 8.29 1.02 1.3 3.5
5 12.5 1.22 1.7 4.6
6 14.7 1.27 1.9 5.0
7 12.1 1.20 1.6 4.4
8 12.9 1.23 1.6 4.5
Control 1 5.51 0.73 1.1 2.9
Control 2 10.8 1.16 1.6 4.3
K193053 - Page 17 of 20

[Table 1 on page 17]
	Hemolysate			y-intercept		Slope	
Deming			-0.0589
95% CI: -0.046-0.164			0.999
95% CI: 0.984-1.015	
Passing-Bablok			-0.0479
95% CI: -0.173-0.060			1.016
95% CI: 1.000-1.034	
Linear Regression			0.215
95% CI:0.139-0.292			0.979
95% CI:0.970-0.988	

[Table 2 on page 17]
	% Bias (Whole	% Relative Bias	% Bias	% Relative Bias
% HbA1c				
	Blood)	(Whole Blood)	(Hemolysate)	(Hemolysate)
				
5%	-0.121	-2.4%	0.031	0.6%
6.5%	-0.076	-1.2%	0.055	0.8%
8%	-0.031	-0.4%	0.078	1.0%
12%	0.089	0.7%	0.142	1.2%

[Table 3 on page 17]
Hemolysate			Precision	Total Error
	%HbA1c	% Bias		
sample			(%CV)	(%)
				
1	4.96	0.63	1.2	3.0
2	6.59	0.87	1.2	3.3
3	7.30	0.94	1.2	3.3
4	8.29	1.02	1.3	3.5
5	12.5	1.22	1.7	4.6
6	14.7	1.27	1.9	5.0
7	12.1	1.20	1.6	4.4
8	12.9	1.23	1.6	4.5
Control 1	5.51	0.73	1.1	2.9
Control 2	10.8	1.16	1.6	4.3

--- Page 18 ---
Total Error Summary – Whole Blood
Whole Blood Precision Total Error
%HbA1c % Bias
Sample (%CV) (%)
1 4.87 -2.56 1.3 5.2
2 6.57 -1.12 1.4 3.8
3 7.34 -0.69 1.4 3.5
4 8.20 -0.30 1.4 3.1
5 12.5 0.84 1.5 3.8
6 14.6 1.15 1.6 4.2
7 12.3 0.79 1.6 3.9
8 13.1 0.93 1.5 3.9
Control 1 5.51 -1.92 1.2 4.3
Control 2 11.1 0.57 1.5 3.6
2. Matrix Comparison:
The effect on Hemoglobin A1c determination, with the Tina-quant Hemoglobin A1cDx
Gen.3 assay, in the presence of anticoagulants was determined on the cobas c 503 analytical
unit by comparing values obtained from samples drawn into K2-EDTA to results obtained
from samples in K3-EDTA, sodium heparin, lithium heparin, NaF/Potassium oxalate, and
EDTA/Fluoride.
41 samples of each anticoagulant and 41 half-filled tubes of each anticoagulant were
evaluated, with %HbA1c concentrations for the sample sets ranging from approximately 5%
to 13%. The filled and corresponding half-filled (double concentrated) sample tubes were
from one donor. Matrix comparison studies were conducted using the Hemolysate
Application and was representative of both Hemolysate and Whole Blood Applications. The
following are results from regression analysis for each matrix (with both full and ½ full
tubes):
K -EDTA
3
Full y = 1.000x + 0.0100 r = 1.000
½ Full y = 1.005 x – 0.0343 r = 1.000
Na Heparin
Full y = 1.008x – 0.0547 r = 1.000
½ Full y = 0.988x + 0.0522 r = 0.999
Li Heparin
Full y = 1.000x r = 1.000
½ Full y = 1.000x – 0.0200 r = 0.999
NaF/Potassium oxalate
Full y = 1.000x r = 1.000
½ Full y = 1.003 x + 0.00472 r = 1.000
K193053 - Page 18 of 20

[Table 1 on page 18]
Whole Blood			Precision	Total Error
	%HbA1c	% Bias		
Sample			(%CV)	(%)
				
1	4.87	-2.56	1.3	5.2
2	6.57	-1.12	1.4	3.8
3	7.34	-0.69	1.4	3.5
4	8.20	-0.30	1.4	3.1
5	12.5	0.84	1.5	3.8
6	14.6	1.15	1.6	4.2
7	12.3	0.79	1.6	3.9
8	13.1	0.93	1.5	3.9
Control 1	5.51	-1.92	1.2	4.3
Control 2	11.1	0.57	1.5	3.6

--- Page 19 ---
EDTA/Fluoride
Full y = 1.000x r = 1.000
½ Full y = 1.000 + 0.0100 r = 1.000
The results support the use of the Tina-quant Hemoglobin A1cDx Gen.3 assay with samples
collected in Li‑heparin, K2‑EDTA, K3‑EDTA, Na‑Heparin, EDTA‑fluoride and
Fluoride/potassium oxalate.
C Clinical Studies:
1. Clinical Sensitivity:
Not applicable.
2. Clinical Specificity:
Not applicable.
3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):
Not applicable.
D Clinical Cut-Off:
Not applicable.
E Expected Values/Reference Range:
The labeling states the following (note that results reported per the International Federation of
Clinical Chemistry, IFCC, are related to results reported per the NGSP as follows: NGSP =
0.915*IFCC+2.15. For additional information see http://www.ngsp.org/ifccngsp.asp):
Protocol 1 (acc. to IFCC): 20‑42 mmol/mol HbA1c.1,2,3,4
Protocol 2 (% HbA1c acc. to DCCT/NGSP): 4.0‑6.0 % HbA1c.
HbA1c levels higher than the upper end of this reference range are an indication of
hyperglycemia during the preceding 2 to 3 months or longer. According to the recommendations
of the American Diabetes Association values above 48 mmol/mol HbA1c (IFCC) or 6.5 %
HbA1c (DCCT/NGSP) are suitable for the diagnosis of diabetes mellitus.32,39 Patients with
HbA1c values in the range of 39‑46 mmol/mol HbA1c (IFCC) or 5.7‑6.4 % HbA1c
(DCCT/NGSP) may be at risk of developing diabetes.5,6
HbA1c levels may reach 195 mmol/mol (IFCC) or 20 % (DCCT/NGSP) or higher in poorly
controlled diabetes. Therapeutic action is suggested at levels above 64 mmol/mol HbA1c (IFCC)
or 8 % HbA1c (DCCT/NGSP). Diabetes patients with HbA1c levels below 53 mmol/mol (IFCC)
or 7 % (DCCT/NGSP) meet the goal of the American Diabetes Association.7,8
K193053 - Page 19 of 20

--- Page 20 ---
HbA1c levels below the established reference range may indicate recent episodes of
hypoglycemia, the presence of Hb variants, or shortened lifetime of erythrocytes.
Each laboratory should investigate the transferability of the expected values to its own patient
population and if necessary determine its own reference ranges.
1. Parnes B, Niebauer L, Holcomb S, et al. Provider Deferred Decisions on Hemoglobin A1c
Report from the Colorado Research Network (CaR) the High Plains Research Network
(HPRN). J Am Fam Med 2006;19(1):20-23.
2. American Diabetes Association Position Statement. Test of Glycemia in Diabetes. Diabetes
Care 2004;27(Suppl 1):91-93.
3. Little RR, Rohlfing C, Wiedmeyer HM, et al. The National Glycohemoglobin
Standardization Program (NGSP): a five year progress report. Clin Chem 2001;47:1985-
1992.
4. Rohlfing CL, Wiedmeyer HM, Little RR, et al. Defining the relationship between plasma
glucose and HbA1c:analysis of glucose profiles and HbA1c in the Diabetes Control and
Complications Trial. Diabetes Care 2002;25:275-278.
5. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of
Diabetes. Diabetes Care 2009;32(7):1327-1334.
6. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010;33(1):62-69.
7. Sacks BW, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory
analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436-472.
8. American Diabetes Association. Standards of Medical Care for patients with diabetes
mellitus. Diabetes Care [Suppl.] 1995;18(1):8-15.
VIII Proposed Labeling:
The labeling supports the finding of substantial equivalence for this device.
IX Conclusion:
The submitted information in this premarket notification is complete and supports a substantial
equivalence decision.
K193053 - Page 20 of 20